Company Profile
Jazz Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- JAZZ
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Ireland
Stock performance
256.65 USD (-1.88%)
Close
Last updated: August 6, 2026
14.2B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, JAZZ closed down 1.88% at $256.65. No new same-company headline was identified in the current news window.
Company overview
Business overview
Jazz Pharmaceuticals is a biopharmaceutical company focused on neuroscience, oncology, and sleep disorder therapies. Its portfolio mixes established commercial products with development programs aimed at extending the company’s specialty franchise.
Geographic Base and Sector Classification
Headquartered in Ireland and listed on NASDAQ, Jazz has a global commercial footprint and a specialty-pharma identity. It sits in neuroscience and oncology rather than broad pharma.
Business Model Characteristics
The company generates value through specialty product sales, lifecycle management, and pipeline development in difficult-to-treat diseases. Investors watch revenue durability, patent and label risk, and the progress of new assets.
Position Within the Biotechnology Landscape
Jazz occupies a steady specialty-biopharma position with catalyst sensitivity around pipeline and label updates. It is more commercial than a pure development-stage biotech name but still reacts to program milestones.
Future catalysts
Jazz Pharmaceuticals’ catalysts are Xywav and oncology franchise execution, plus any pipeline update that extends the sleep-and-cancer mix. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Jazz Pharmaceuticals (JAZZ)?
Jazz Pharmaceuticals (JAZZ) most recently closed at 256.65 USD, a -1.88% move versus the previous session.
What is the market cap of Jazz Pharmaceuticals (JAZZ)?
Jazz Pharmaceuticals currently has a market capitalization of 14.2B USD on BioPharmSignal.
What does Jazz Pharmaceuticals do?
Jazz Pharmaceuticals is a biopharmaceutical company focused on neuroscience, oncology, and sleep disorder therapies. Its portfolio mixes established commercial products with development programs aimed at extending the company’s specialty franchise.
On which exchange is JAZZ stock listed?
Jazz Pharmaceuticals (JAZZ) is associated with NASDAQ, Ireland, Biopharma.
What is Jazz?
Jazz Pharmaceuticals’ catalysts are Xywav and oncology franchise execution, plus any pipeline update that extends the sleep-and-cancer mix.
Which conditions is Jazz Pharmaceuticals targeting with Jazz?
Jazz Pharmaceuticals is associated with oncology, cancer therapeutics, neuroscience based on its company overview and current catalyst commentary.
How does Jazz Pharmaceuticals describe recent progress with Jazz?
Jazz Pharmaceuticals’ catalysts are Xywav and oncology franchise execution, plus any pipeline update that extends the sleep-and-cancer mix.
What is Pharmaceuticals?
Jazz Pharmaceuticals is a biopharmaceutical company focused on neuroscience, oncology, and sleep disorder therapies.